Rayca Precision Oy
Rayca Precision Oy is building pharma’s foundation for molecular superintelligence: a world model of drug development designed to resolve clinical attrition before synthesis. While modern AI can design almost any candidate, programs across small molecules, peptides, antibodies, and degraders still fail because critical developability liabilities (toxicity, stability, delivery, and formulation) are evaluated too late.
Rayca integrates an institutional molecular memory architecture, an adaptive Bio x AI compute engine, and partner-enabled cloud-lab experimentation. By turning past program failures and fragmented pipeline data into active design intelligence, Rayca helps biopharma teams engineer therapeutic candidates that are born developable. The company partners with discovery-stage biotechs and global pharma through platform licensing, scoped pilot deployments, and therapeutic co-development.
#AI
#Pharma